- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Aurinia Pharmaceuticals is a biotechnology business based in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.24 – an increase of 2.4% over the previous week. Aurinia Pharmaceuticals employs 300 staff and has a trailing 12-month revenue of around $207.1 million.
What's in this guide?
Our top picks for where to buy Aurinia Pharmaceuticals stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Aurinia Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – AUPH. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Aurinia Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Aurinia Pharmaceuticals stock price (NASDAQ: AUPH)
Use our graph to track the performance of AUPH stocks over time.Aurinia Pharmaceuticals shares at a glance
Information last updated 2024-10-25.
| Latest market close | $7.24 |
|---|---|
| 52-week range | $4.71 - $10.05 |
| 50-day moving average | $6.91 |
| 200-day moving average | $6.09 |
| Wall St. target price | $9.77 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.35 |
Is it a good time to buy Aurinia Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aurinia Pharmaceuticals price performance over time
Historical closes compared with the close of $7.05 from 2024-10-25
| 1 week (2024-10-22) | -0.28% |
|---|---|
| 1 month (2024-09-27) | -3.16% |
| 3 months (2024-07-29) | 24.12% |
| 6 months (2024-04-29) | 40.72% |
| 1 year (2023-10-27) | -1.95% |
|---|---|
| 2 years (2022-10-28) | -12.09% |
| 3 years (2021-10-29) | 33.08 |
| 5 years (2019-10-29) | 44.47% |
Aurinia Pharmaceuticals financials
| Revenue TTM | $207.1 million |
|---|---|
| Gross profit TTM | $83.4 million |
| Return on assets TTM | -5.48% |
| Return on equity TTM | -13.3% |
| Profit margin | -24.31% |
| Book value | $2.55 |
| Market Capitalization | $1 billion |
TTM: trailing 12 months
Aurinia Pharmaceuticals share dividends
We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.
Have Aurinia Pharmaceuticals's shares ever split?
Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 22 October 2013 . So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.
Aurinia Pharmaceuticals share price volatility
Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as $4.71 up to $10.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 1.445. This would suggest that Aurinia Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aurinia Pharmaceuticals overview
Aurinia Pharmaceuticals Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. , Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. .
Frequently asked questions
What percentage of Aurinia Pharmaceuticals is owned by insiders or institutions?Currently 7.072% of Aurinia Pharmaceuticals shares are held by insiders and 44.466% by institutions. How many people work for Aurinia Pharmaceuticals?
Latest data suggests 300 work at Aurinia Pharmaceuticals. When does the fiscal year end for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals's fiscal year ends in December. Where is Aurinia Pharmaceuticals based?
Aurinia Pharmaceuticals's address is: 118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6 What is Aurinia Pharmaceuticals's ISIN number?
Aurinia Pharmaceuticals's international securities identification number is: CA05156V1022 What is Aurinia Pharmaceuticals's CUSIP number?
Aurinia Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 05156V102
More resources on Finder
More guides on Finder
-
How to buy Zentek stock (ZTEK)
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
-
How to buy ATAI Life Sciences stock (Atai Life Sciences)
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
-
How to buy Seelos Therapeutics stock (SEEL)
Steps to owning and managing SEEL, with 24-hour and historical pricing before you buy.
-
How to buy Eli Lilly and Company stock (LLY)
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
-
How to buy Humana stock (HUM)
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
-
How to buy Illumina stock (ILMN)
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
-
How to buy UnitedHealth Group Incorporated stock (UNH)
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
-
How to buy Pfizer stock (PFE)
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
-
How to buy Moderna stock (MRNA)
Steps to owning and managing MRNA, with 24-hour and historical pricing before you buy.
-
How to buy Johnson & Johnson stock (JNJ)
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Ask a question